CRC

Morehouse School of Medicine and Freenome Present Research Demonstrating High Enrollment Rates for African Americans in Clinical Trial

Wednesday, October 27, 2021 - 1:00pm

PREEMPT CRC, Freenome's multi-center clinical study on colorectal cancer, is in the final stages of enrollment.

Key Points: 
  • PREEMPT CRC, Freenome's multi-center clinical study on colorectal cancer, is in the final stages of enrollment.
  • The history of abuse in the name of research has created real and well-founded fear and skepticism among African Americans[1].
  • Clinical trials often have low enrollment of African Americans due to this mistrust, in addition to communication issues with providers, socioeconomic factors and an overall lack of access to clinical trials.
  • "Working closely with Freenome, we're able to demonstrate successful enrollment, hopefully setting standards for other clinical trials and their enrollment within African American communities."

Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting

Tuesday, October 26, 2021 - 1:00pm

We are excited to see the positive results of this real-world, independent study of the Pure-Vu System supporting both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting.

Key Points: 
  • We are excited to see the positive results of this real-world, independent study of the Pure-Vu System supporting both inpatient and outpatient procedures for screening and emergency colonoscopies at the ACG meeting.
  • Of the 40 procedures that we completed, the Pure-Vu was used as an adjunct to IBP to allow completion of procedure in 37 patients.
  • Additionally, we successfully completed three procedures without any bowel preparation in patients with lower GI bleeds.
  • In patients with IBP, the mean BBPS score improved from 3.1 (range: 0-6) to 8.5 (range 5-9) after intra-procedural cleansing.

Best’s Market Segment Report: AM Best Places Negative Outlook on Costa Rica’s Insurance Market

Monday, October 25, 2021 - 2:56pm

AM Best has assigned a negative market segment outlook on Costa Ricas insurance industry, owing to the COVID-19 pandemic, which has impacted economic activity and public finances.

Key Points: 
  • AM Best has assigned a negative market segment outlook on Costa Ricas insurance industry, owing to the COVID-19 pandemic, which has impacted economic activity and public finances.
  • The new Bests Market Segment Report, titled, Market Segment Outlook: Costa Rica Insurance, notes that as of December 2020, Costa Ricas insurance market registered CRC 842 billion (USD 1.4 billion) in premiums, with year-over-year growth of 1.1%, slower than previous periods, primarily due to the economic conditions caused by the pandemic.
  • Beginning July 2021, the market grew 9.2%, mainly driven by the recovery of the compulsory insurance occupational injury risk market, as well as sustained growth of the voluntary insurance business lines, despite a slowdown in the auto market.
  • AM Best will continue to monitor the economic political, and regulatory landscape and the impact on Costa Ricas insurance industry.

Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer

Monday, October 25, 2021 - 1:05pm

Additionally, the blood-based test identified 90% of patients with asymptomatic Stage 1 or 2 CRC, suggesting the test may have meaningful performance in an average-risk screening population.

Key Points: 
  • Additionally, the blood-based test identified 90% of patients with asymptomatic Stage 1 or 2 CRC, suggesting the test may have meaningful performance in an average-risk screening population.
  • The LUNAR-2 blood test aims to detect early-stage cancer in screen-eligible asymptomatic adults from a simple blood draw.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

CCam® focus Showcased Remote Hybrid Research Tools at Corporate Researchers Conference 2021

Monday, October 25, 2021 - 1:00pm

GREENWICH, Conn., Oct. 25, 2021 /PRNewswire-PRWeb/ -- Civicom CCam focus was a sponsor of the Insights Association Corporate Researchers Conference 2021 in Dallas, Texas held October 20-22.

Key Points: 
  • GREENWICH, Conn., Oct. 25, 2021 /PRNewswire-PRWeb/ -- Civicom CCam focus was a sponsor of the Insights Association Corporate Researchers Conference 2021 in Dallas, Texas held October 20-22.
  • CCam showcased its HD 360 recording and streaming solution that brings hybrid capabilities to in-person research, demonstrating how in-depth interviews, focus groups, product testing, taste test research, medical device testing and more can be done from anywhere with CCam focus.
  • CCam focus' state-of-the-art recording and streaming platform gives clients, moderators, and researchers capabilities to conduct research with remote moderation and observation in combination with in-person respondents.
  • Civicom CCam focus is an HD 360 recording and streaming solution for in-person research, ideal for the new safety protocols.

Freenome Shows Continued Leadership in Colorectal Cancer Research

Monday, October 25, 2021 - 1:00pm

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology (ACG) annual meeting that underscores their commitment to improving colorectal cancer (CRC) screening.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Freenome, a privately held biotech company, presented new research at the American College of Gastroenterology (ACG) annual meeting that underscores their commitment to improving colorectal cancer (CRC) screening.
  • Freenome is developing a CRC screening test using a routine blood draw to detect cancer in its earliest stages.
  • PREEMPT CRC, Freenome's multi-center clinical study on colorectal cancer, is in the final stages of enrollment.
  • Freenome is a biotechnology company with the most comprehensive multiomics platform for early cancer detection using a routine blood draw.

Cat Rock Capital Sends Letter to Just Eat Takeaway.com (“JET”) Board Urging Sale or Spin-Off of Grubhub by End of 2021

Monday, October 25, 2021 - 9:00am

Cat Rock Capital Management LP is a long-term focused investment firm that manages capital on behalf of pension funds, endowments, foundations, and other institutional investors.

Key Points: 
  • Cat Rock Capital Management LP is a long-term focused investment firm that manages capital on behalf of pension funds, endowments, foundations, and other institutional investors.
  • Cat Rock Capital is based in Connecticut, USA and was founded in 2015 by Alex Captain.
  • Cat Rock Capital Management LP and certain of its affiliates and controlling persons (collectively, Cat Rock Capital), is publishing this announcement solely for the information of other shareholders in Just Eat Takeaway.com NV (Just Eat Takeaway.com).
  • Cat Rock Capital is subject to supervision by, and registered with, the U.S. Securities and Exchange Commission.

Servier announces outcome from the primary analysis of the Phase III SOLSTICE trial assessing LONSURF® (trifluridine/tipiracil) + bevacizumab in a 1st line setting for patients with unresectable mCRC non-eligible for intensive therapy

Friday, October 22, 2021 - 8:00am

SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.

Key Points: 
  • SOLSTICE was designed to evaluate the superiority of LONSURF (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.
  • D., Head of Late Stage and Life Cycle Management, and Deputy Head Oncology and Immuno-Oncology Therapeutic Area, Servier.
  • The clinical value of LONSURF in its current indications remains unchanged, and the ongoing Phase III SUNLIGHT trial (LONSURF + bevacizumab versus LONSURF in 3rd line mCRC) is proceeding as planned.
  • SOLSTICE is an open-label, randomized, multicentre Phase III trial in 856 unresectable metastatic colorectal cancer patients who are not candidates for, or do not require, intensive therapy.

CRC Releases 2020 Sustainability Update Detailing Performance Metrics

Thursday, October 21, 2021 - 10:00pm

California Resources Corporation (NYSE: CRC) (CRC or the Company) today announced the publication of its 2020 Sustainability Update .

Key Points: 
  • California Resources Corporation (NYSE: CRC) (CRC or the Company) today announced the publication of its 2020 Sustainability Update .
  • The update provides details of CRCs key environmental, social and governance (ESG) performance metrics as well as progress on its established 2030 Sustainability goals.
  • The 2020 Sustainability Update focuses on performance during 2020, 2019 and 2018 and is complemented by the new SASB and API templates.
  • Highlights and achievements from the 2020 Sustainability Update include:
    For more information about ESG at CRC, please visit our ESG page at https://crc.com/esg .

Walmart to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Screening Test

Tuesday, October 19, 2021 - 11:39am

IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the Company) today announced that Walmart has begun in-store sales and rollout of the Companys EZ Detect colorectal disease screening test within the nationwide Walmart retail system.

Key Points: 
  • IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the Company) today announced that Walmart has begun in-store sales and rollout of the Companys EZ Detect colorectal disease screening test within the nationwide Walmart retail system.
  • The in-store retail placement follows Biomericas previous announcement in early October, that Walmart had begun sales of EZ Detect product for online purchase through Walmart.com ( https://www.walmart.com/ip/EZ-Detect-Colon-Disease-Test-Kit/577079744 ).
  • The EZ Detect colon disease screening test is the simplest at-home test to detect occult (hidden) blood in a persons stool, which can be an early warning sign of colorectal diseases, including colon and rectal cancers.
  • A person simply places an EZ Detect test pad into the toilet after a bowel movement.